~~<i id='33B1AA2100'><strike id='33B1AA2100'><tt id='33B1AA2100'><pre id='33B1AA2100'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

entertainment

author：knowledge 2025-10-01 15:38:57 - browse：94

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Can U.S. cancer drug shortages be fixed?

explore

focus

explore

focus

explore

hotspot

SerialbiotechentrepreneurBobLangerwillserveasanadvisertoT.rxCapital.PatGreenhouse/GlobeStaffExecutiv

WSS

People can get long Covid without testing positive for virus: Study

Hospital at home shows how to bring innovation to health care

Health officials lay out plans to cope with respiratory virus season

With clinical trial data readouts, here's how to spot spin

How to make over

Former Pear Therapeutics executives start new VC firm

focus

entertainment

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

Health officials lay out plans to cope with respiratory virus season

As demand for Covid shots wanes, Moderna seeks its next success

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

U.K. Biobank has 500,000 peoples' genome sequences available

Hepatitis C has a cure — but many Americans still lack access to it

Fetal surgery at risk from Dobbs and new abortion restrictions

Medicare details structure of new drug price negotiation program

U.K. Biobank has 500,000 peoples' genome sequences available

focus

Mayo Clinic plans $5B tech

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Abortion policy in the spotlight at Republican debate

PBMs are inflating the cost of generic drugs. They must be reined in

ReNAgade cuts staff seven months after raising $300 million

explore

focus

explore

hotspot